Impact of Thyroid Disorders on the Incidence of Non-alcoholic Fatty Liver Disease in Germany

Overview

Journal United European Gastroenterol J

Publisher Wiley

Specialty Gastroenterology

Date 2021 Jul 21

PMID 34288580

Citations 3

Authors

Christian Labenz

Karel Kostev

Angelo Armandi

Peter R Galle

Jorn M Schattenberg

Affiliations

Soon will be listed here.

Abstract

Background: Studies investigating a potential association between hypothyroidism and non-alcoholic fatty liver disease (NAFLD) showed conflicting results and large-scale population-based data from Germany on this topic are currently missing.

Objective: It was the aim of this analysis to investigate the impact of thyroid gland disorders on the prevalence of NAFLD in Germany.

Methods: In this case-control study, using the German disease Analyzer database (IQVIA), NAFLD patients were matched to patients without NAFLD by age, sex, index year, treating physician, diabetes mellitus type II, and obesity. The main outcome of the study was an association between thyroid gland disorders (hypothyroidism, hyperthyroidism and autoimmune thyroiditis) and incident NAFLD and was evaluated using logistic regression analyses.

Results: 57,483 patients with NAFLD were matched to 57,483 patients without liver disease. Mean age of the cohort was 60.3 years (±14.1) and 52.3% were men. In regression analyses, hypothyroidism (OR 1.17, 95% CI 1.10 - 1.24, p < 0.001) as well as autoimmune thyroiditis (OR 1.53, 95% CI 1.35-1.73, p < 0.001) were associated with a higher risk of NAFLD. In contrast, hyperthyroidism was associated with a lower risk of NAFLD (OR 0.85, 95% CI 0.77-0.94, p < 0.001). The effect of hypothyroidism on the prevalence of NAFLD remained significant across men (OR 1.31, 95% CI 1.15-1.48) as well as women (OR 1.12, 95% CI 1.05-1.21).

Conclusion: Hypothyroidism seems to be a risk factor for incident NAFLD.

Citing Articles

Thyroid disorders and the incidence of type 2 diabetes: insights from a 10-year cohort study in Germany.

Sarabhai T, Kostev K Endocr Connect. 2025; 14(3).

PMID: 39831884 PMC: 11799829. DOI: 10.1530/EC-24-0554.

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.

Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y BMC Med. 2024; 22(1):101.

PMID: 38448943 PMC: 10919055. DOI: 10.1186/s12916-024-03315-0.

Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease.

Vidal-Cevallos P, Murua-Beltran Gall S, Uribe M, Chavez-Tapia N Int J Mol Sci. 2023; 24(19).

PMID: 37834051 PMC: 10572395. DOI: 10.3390/ijms241914605.

Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany.

Labenz C, Kostev K, Armandi A, Galle P, Schattenberg J United European Gastroenterol J. 2021; 9(7):829-836.

PMID: 34288580 PMC: 8435260. DOI: 10.1002/ueg2.12124.

References

Kaps L, Labenz C, Galle P, Weinmann-Menke J, Kostev K, Schattenberg J . Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020; 8(8):942-948. PMC: 7707877. DOI: 10.1177/2050640620944098. View

Younossi Z, Tacke F, Arrese M, Sharma B, Mostafa I, Bugianesi E . Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2018; 69(6):2672-2682. DOI: 10.1002/hep.30251. View

Labenz C, Huber Y, Michel M, Nagel M, Galle P, Kostev K . Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun. 2020; 4(9):1293-1301. PMC: 7471420. DOI: 10.1002/hep4.1541. View

Jiang L, Du J, Wu W, Fang J, Wang J, Ding J . Sex differences in subclinical hypothyroidism and associations with metabolic risk factors: a health examination-based study in mainland China. BMC Endocr Disord. 2020; 20(1):100. PMC: 7339542. DOI: 10.1186/s12902-020-00586-5. View

Rathmann W, Bongaerts B, Carius H, Kruppert S, Kostev K . Basic characteristics and representativeness of the German Disease Analyzer database . Int J Clin Pharmacol Ther. 2018; 56(10):459-466. DOI: 10.5414/CP203320 . View

Ness G, Pendleton L, Li Y, Chiang J . Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun. 1990; 172(3):1150-6. DOI: 10.1016/0006-291x(90)91568-d. View

Huber Y, Labenz C, Michel M, Worns M, Galle P, Kostev K . Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. Dtsch Arztebl Int. 2021; 117(43):719-724. PMC: 7871444. DOI: 10.3238/arztebl.2020.0719. View

Marjot T, Moolla A, Cobbold J, Hodson L, Tomlinson J . Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2019; 41(1). DOI: 10.1210/endrev/bnz009. View

Thompson G, Soutar A, Spengel F, Jadhav A, Gavigan S, MYANT N . Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A. 1981; 78(4):2591-5. PMC: 319395. DOI: 10.1073/pnas.78.4.2591. View

10.

Angelin B, Kristensen J, Eriksson M, Carlsson B, Klein I, Olsson A . Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J Intern Med. 2014; 277(3):331-342. DOI: 10.1111/joim.12261. View

11.

Schattenberg J, Lazarus J, Newsome P, Serfaty L, Aghemo A, Augustin S . Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int. 2021; 41(6):1227-1242. PMC: 8252761. DOI: 10.1111/liv.14825. View

12.

Labenz C, Kostev K, Armandi A, Galle P, Schattenberg J . Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. United European Gastroenterol J. 2021; 9(7):829-836. PMC: 8435260. DOI: 10.1002/ueg2.12124. View

13.

Kihara S, Wolle J, Ehnholm C, Chan L, Oka K . Regulation of hepatic triglyceride lipase by thyroid hormone in HepG2 cells. J Lipid Res. 1993; 34(6):961-70. View

14.

Martinez Escude A, Pera G, Arteaga I, Exposito C, Rodriguez L, Toran P . Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. Med Clin (Barc). 2019; 154(1):1-6. DOI: 10.1016/j.medcli.2019.03.018. View

15.

Lazarus J, Colombo M, Cortez-Pinto H, Huang T, Miller V, Ninburg M . NAFLD - sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol. 2020; 17(7):377-379. DOI: 10.1038/s41575-020-0315-7. View

16.

Hagstrom H, Adams L, Allen A, Byrne C, Chang Y, Gronbaek H . Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology. 2021; 74(1):474-482. PMC: 8515502. DOI: 10.1002/hep.31726. View

17.

Schattenberg J, Loomba R . Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis. Hepatology. 2018; 69(3):934-936. DOI: 10.1002/hep.30402. View

18.

Perra A, Simbula G, Simbula M, Pibiri M, Kowalik M, Sulas P . Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J. 2008; 22(8):2981-9. DOI: 10.1096/fj.08-108464. View

19.

Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J . Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213):2012-2024. DOI: 10.1016/S0140-6736(19)32517-6. View

20.

Labenz C, Kostev K, Alqahtani S, Galle P, Schattenberg J . Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2021; 130(3):172-177. DOI: 10.1055/a-1378-4679. View